Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 19

recruiting
3 968
countries
28
conditions
2 103

677 trials match your criteria

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Study on the Use of Landiolol Hydrochloride and Sodium Chloride for Patients Undergoing Mitral Valve Surgery to Prevent Low-Cardiac Output Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ponatinib

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab

Study on Preventing Cardiovascular Collapse in Critically Ill Adults Using Noradrenaline Tartrate During Tracheal Intubation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Noradrenaline Tartrate
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.